Eli Lilly's retatrutide clears late-stage obesity trial with 28% weight loss

On May 21, 2026, Eli Lilly announced its next-generation 'triple-G' drug retatrutide cleared a crucial late-stage obesity trial, with patients on the highest dose losing an average 28.3% of body weight (about 70 lbs) over 80 weeks. Roughly 65% on the top dose fell below the obesity BMI threshold. The results move the weekly injection closer to an FDA filing.